Latest From Biotech Now

Five Countries, One Goal: Collaboration with Global Impact in the Life Sciences Industry

MLSC

During the 2013 BIO International Convention, the Massachusetts Life Sciences Center (MLSC) and regions from four other countries launched the new International Collaborative Industry Program (ICIP). The MLSC will partner with Victoria, Australia; the Wallonia region of Belgium; Quebec, Canada; and Alsace in France to award funding to projects promoting innovative and collaborative research and development (R&D) between companies in Massachusetts and in the partnering regions. The program’s goal is to develop long-term collaborations to advance late-stage R&D projects in biotechnology, pharmaceuticals, medical Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Inside Health Policy: Clearing Up Confusion About Bills Updating Vaccine Tax Code

Syringes

Inside Health Policy’s Alaina Busch wrote a story today on confusion that has been spreading recently related to vaccines excise legislation. Vaccines protect people from seasonal flu, and new strains have recently been approved to further protect public health. As such, the vaccine excise tax must in turn be updated to include recent approvals. S. 391 and H.R. 475 update the existing excise tax to cover the newest seasonal influenza vaccines. The legislation does not Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

What OxyContin Tells Us About the Value of “Evergreening” and Patents

Be.Futureproof

A few weeks ago, the  FDA announced that they would not allow generic versions of older versions of OxyContin. The original formulation of OxyContin goes off patent today. The original formulation did not have “tamper-resistant qualities” that prevent people from “crushing, breaking, and dissolution using a variety of tools and solvents.”  The article reports that the decision will keep Teva Pharmaceuticals and Impax Laboratories from making the older version which the FDA has determined is too dangerous Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,

Biopharmaceuticals and Accountable Care Organizations: Balancing Cost and Quality

Biopharmaceuticals and Accountable Care Organizations: Balancing Cost and Quality

As biopharmaceutical manufacturers consider the new reality of accountable care organizations (ACOs) and the impact on their businesses, they must be ready to demonstrate the value of their products in ways that recognize the fine balance of cost and quality that ACO and ACO-like models seek to achieve. According to panelists speaking at the 2013 BIO International Convention session entitled, “Accountable Care Organization (ACO) Framework for Biopharmaceuticals,” there are three primary considerations when it comes Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

BioGENEius – From Student Participant to Judge

BioGENEius – From Student Participant to Judge

It’s been two years since I participated as a student in BioGENEius. Last year I presented my work at the White House Science Fair and now I am privileged to attend BioGENEius 2013 as a judge. BioGENEius 2013 is in Chicago this year and as a student at Northwestern University in nearby Evanston, I jumped at the chance to attend again. As I joined the judges and learned about their backgrounds, I felt honored to Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,